LYTAP-001

A small (5 amino acid) cyclic peptide that binds to the EGF-binding site on the extra-cellular arm of EGFR and leads to the sequestration of EGFR by non-clathrin endocytosis.

This binding site is highly conserved, leading to LYTAP-001 inhibiting EGFR activation despite a range of common EGFR mutations.

The receptor-ligand complex then undergoes lysosomal degradation, resulting in an almost complete (98%) reduction in EGFR recycling back to the surface of the cell.

LYTAP-001 currently is undergoing pre-clinical, IND-enabling studies as an oral drug with a first-in-human study expected to start in 2026.